Roanoke Asset Management Corp NY decreased its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 9.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 19,493 shares of the medical research company’s stock after selling 1,975 shares during the quarter. Amgen accounts for approximately 1.6% of Roanoke Asset Management Corp NY’s investment portfolio, making the stock its 18th largest position. Roanoke Asset Management Corp NY’s holdings in Amgen were worth $3,390,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Toronto Dominion Bank lifted its position in Amgen by 11.0% during the third quarter. Toronto Dominion Bank now owns 279,280 shares of the medical research company’s stock worth $52,066,000 after purchasing an additional 27,726 shares during the period. Teacher Retirement System of Texas lifted its position in Amgen by 16.5% during the third quarter. Teacher Retirement System of Texas now owns 740,764 shares of the medical research company’s stock worth $138,115,000 after purchasing an additional 104,871 shares during the period. Pacer Advisors Inc. lifted its position in Amgen by 10.3% during the second quarter. Pacer Advisors Inc. now owns 25,378 shares of the medical research company’s stock worth $4,371,000 after purchasing an additional 2,362 shares during the period. Putnam FL Investment Management Co. bought a new stake in Amgen during the third quarter worth about $447,000. Finally, Wesbanco Bank Inc. lifted its position in Amgen by 6.5% during the second quarter. Wesbanco Bank Inc. now owns 106,792 shares of the medical research company’s stock worth $18,393,000 after purchasing an additional 6,492 shares during the period. 78.61% of the stock is owned by institutional investors and hedge funds.
Several research firms recently weighed in on AMGN. Leerink Swann reaffirmed a “market perform” rating on shares of Amgen in a research report on Friday, February 2nd. Atlantic Securities cut shares of Amgen from an “overweight” rating to a “neutral” rating and set a $187.01 target price for the company. in a report on Monday, February 5th. Vetr cut shares of Amgen from a “hold” rating to a “sell” rating and set a $181.60 target price for the company. in a report on Tuesday. BidaskClub raised shares of Amgen from a “sell” rating to a “hold” rating in a report on Thursday, January 18th. Finally, Oppenheimer set a $205.00 target price on shares of Amgen and gave the stock a “buy” rating in a report on Friday, January 5th. One equities research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. Amgen currently has an average rating of “Hold” and a consensus price target of $191.72.
Amgen, Inc. (AMGN) opened at $190.35 on Wednesday. The stock has a market cap of $137,000.50, a P/E ratio of 74.07, a P/E/G ratio of 2.27 and a beta of 1.37. Amgen, Inc. has a fifty-two week low of $152.16 and a fifty-two week high of $201.23. The company has a quick ratio of 5.17, a current ratio of 5.49 and a debt-to-equity ratio of 1.35.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Thursday, February 1st. The medical research company reported $2.89 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.03 by ($0.14). The business had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.84 billion. Amgen had a net margin of 8.66% and a return on equity of 30.87%. The firm’s quarterly revenue was down 2.7% compared to the same quarter last year. During the same quarter last year, the business earned $2.89 EPS. equities analysts expect that Amgen, Inc. will post 13.21 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 8th. Investors of record on Thursday, February 15th will be issued a $1.32 dividend. This represents a $5.28 dividend on an annualized basis and a yield of 2.77%. The ex-dividend date is Wednesday, February 14th. This is a positive change from Amgen’s previous quarterly dividend of $1.15. Amgen’s dividend payout ratio (DPR) is 205.45%.
Amgen announced that its board has authorized a share repurchase plan on Thursday, February 1st that permits the company to buyback $10.00 billion in shares. This buyback authorization permits the medical research company to reacquire shares of its stock through open market purchases. Shares buyback plans are often a sign that the company’s board believes its stock is undervalued.
In related news, EVP Sean E. Harper sold 1,525 shares of the firm’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $185.62, for a total value of $283,070.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last quarter, insiders sold 4,575 shares of company stock valued at $818,361. 0.19% of the stock is owned by company insiders.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).